PRAME Cell Therapy Shrinks Eye Cancer Tumors in Every Patient

The PRAME Cell Therapy results are the kind of early data that makes oncologists lean forward: in a small Phase 1b trial, every one of sixteen patients with an aggressive eye cancer saw their tumors shrink after a single infusion of engineered immune cells, according to data presented by a University of Colorado oncologist and profiled by STAT on Wednesday. The trial targeted uveal melanoma, a rare cancer of the eye that usually spreads to the liver and has few effective treatments once it does.

The therapy, called anzu-cel and developed by the German biotech Immatics, is a T-cell therapy aimed at a protein named PRAME that shows up on melanoma cells and several other stubborn tumors. Patients had their own immune cells collected, genetically reprogrammed to recognize PRAME, and infused back in a single dose. Tumor shrinkage was observed in the full group of sixteen, a striking outcome in a population that had already exhausted a median of two prior rounds of treatment.

Look closer and the numbers stay strong. Roughly two-thirds of patients had a confirmed response, nearly nine in ten had their disease controlled, and the median response lasted about eleven months. The median time before the cancer started growing again was around eight and a half months, and median overall survival had not yet been reached — more than seven in ten patients were alive a year after treatment, according to a company summary of the data. Liver tumors, the deadliest site of spread in this disease, shrank by about half on average.

Why these sixteen patients matter

Context makes the outcome harder to dismiss. More than four in five of the participants had cancer in both the liver and other organs, and the median tumor burden was large — these were not easy cases. Nearly two-thirds of the group had already received a related immune therapy, and ten of those eleven patients still saw their tumors shrink or stabilize with the new cell therapy. That hints the PRAME Cell Therapy can work even after similar approaches have failed, a rare property in cancer medicine.

Safety looked manageable. The most common serious side effect was low blood-cell counts tied to the lymph-depleting chemotherapy given before the infusion, a standard part of cell-therapy protocols. Cytokine release syndrome — an immune overreaction — occurred in most patients but was largely mild, and severe brain-related toxicity was uncommon. Treatment-related deaths were not the story here; durable shrinkage was.

The bigger target behind the bull's-eye

What excites researchers beyond this one eye cancer is the target itself. PRAME also appears in cutaneous melanoma and shows up in pancreatic and ovarian tumors, cancers where immunotherapy has largely stumbled. "This can be taken forward in other areas of oncology," oncologist Sapna Patel told the conference where the data debuted, as reported by STAT. The company has already tested the approach in broader melanoma groups and is planning a Phase 2 expansion trial to confirm the findings in more patients.

For comparison, another small immunotherapy trial made similar waves: at Memorial Sloan Kettering, every patient with a particular type of rectal cancer saw their tumor vanish after months of the immunotherapy drug dostarlimab, with no surgery needed. Different disease, different drug — but the pattern is the same: immune-based approaches are posting results in niches where standard treatment once felt like a dead end, and each success sharpens the question of which patients should get them first.

The caveats are real and worth stating plainly. Sixteen patients is a tiny sample, Phase 1 trials are designed to test safety more than prove benefit, and the lymph-depleting chemotherapy required before the cell infusion carries its own risks. Prices for approved cell therapies routinely run into six figures, so even if this approach reaches the market, access will be a fight. And investors should remember that many promising Phase 1 signals never survive larger trials.

Still, the trajectory is hard to ignore. A decade ago, engineering a patient's own T cells to hunt a single protein on eye-cancer cells sounded like science fiction; today it has shrunk tumors in every patient in a difficult-to-treat group. For readers following cancer research — new blood tests are catching relapses earlier, and outbreak science keeps moving fast too — this is one more signal that the next wave of oncology is personal. Even lifestyle research is showing up on scans; the lab and the clinic are converging.

Sources: STAT, OncoDaily, Cure Melanoma.